Clinical Trials Logo
  1. Home
  2. Severe Eosinophilic Asthma
  3. NCT04126499

Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain — ORBE  

Severe Eosinophilic Asthma Clinical Trial

Official title:
Observational Retrospective Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain

Clinical Trial Summary

Observational, retrospective study in adults (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who at the discretion of the investigator were candidates to receive benralizumab in the individualized access program approved by national health authorities. Primary Objective: To describe the demographic and baseline characteristics in patients with severe eosinophilic asthma who participated in the individualized access program approved in Spain and received at least one dose of benralizumab. Secondary Objectives: To describe clinical outcomes in severe eosinophilic asthma patients who received at least three doses of benralizumab in the individualized access program.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04126499
Study type Observational
Source AstraZeneca
Contact
Status Completed
Phase
Start date January 13, 2020
Completion date May 8, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Completed NCT02560610 - Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Phase 2
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Not yet recruiting NCT03652376 - Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Phase 4
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Completed NCT05180357 - RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Active, not recruiting NCT03833141 - Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
Completed NCT05271526 - Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Not yet recruiting NCT06302959 - Clock Proteins as Prognostic Markers
Recruiting NCT05440656 - A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
Completed NCT04159519 - A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Phase 4
Completed NCT03907137 - Real World Study With Benralizumab in Severe Asthma in Switzerland
Active, not recruiting NCT04084613 - Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
Recruiting NCT06465485 - STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Phase 3
Recruiting NCT03739320 - A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma